KNOWLEDGE / Publication / POST
August 7, 2017

Scientific Poster Publication made on April 2017 at the SIPS Conference on Placebo Studies, Leiden (Netherlands).

In analgesia randomized clinical trials (RCTs), the magnitude of the placebo response has a negative influence when testing the statistically significant superiority of active compounds compared to placebo. In chronic pain, meta-analyses have already highlighted the baseline pain amongst the many parameters correlated with the placebo response.

One of the objectives of this study was to investigate the relationship between the placebo response and the baseline pain intensity collected by the average pain intensity (API), the brief pain inventory (BPI), etc. Eighty-eight patients with peripheral neuropathic pain were enrolled and blindly given a placebo in addition to their regular analgesic treatment during 4 weeks. The multiple endpoints (placebo responses) were estimated as the pain differences between baseline and the end of the treatment, computed with the API, BPI, etc.

As expected, the baseline pain measures were significantly correlated between each other and with their respective placebo response (API-baseline correlated with API improvement, etc). To go further in the prediction, we combined the baselines in a global pain intensity scale which turned not to be correlated with any placebo responses. However, this scale can be used to estimate if a patient has over-evaluated his baseline pain which then correlated with the multiple endpoints. Indeed, a patient with an over-estimated baseline pain has more chances to show a pain improvement.

Those results challenge the classical view of the baseline pain in the placebo response. An alternative use of the multiple baseline measurements could then help to predict the placebo response, a major confounding factor, in RTCs

Scientific Poster
Alvaro Pereira, PHD; Samuel Branders, PHD; Christian Dualé, MD PHD; Fréderic Clermont, PHD; Pierre Gramme, MS; Chantal Gossuin, PHARMD; Dominique Demolle, PHD
April 1, 2017
SIPS Conference


Senior Project Leader

Related content


Correcting For The Individual Patient Regression To The Mean Effect

Often, the primary endpoint of RCTs is defined as a change from baseline of a continuous outcome. In…

Type: Scientific Poster
Authors: Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD
Conference: American Society for Clinical Pharmacology and Therapeutics
Read More

Do Environmental Parameters Influence The Prediction Of The Placebo Response?

This proof-of-concept study on peripheral neuropathic pain patients investigates the potential influence of the investigator on the placebo…

Read More

Bayesian Modeling Of The Placebo Response In Neuropathic Pain

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response have a negative…

Type: Scientific Poster
Authors: Samuel Branders, PhD; Alvaro Pereira, PhD; Frederic Clermont, PhD; Chantal Gossuin; Dominique Demolle, PhD
Conference: Promoting Statistical Insight Conference
Read More

The next frontier in clinical research & patient management

We’re proud to be leading the charge into the next era of drug development.
Cognivia helps clinical trials reduce data variability, empower decision-making, and accelerate the launch of new therapies.
Tell us about your clinical trial below and we’ll be in touch.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.